Announcement of Licensing Agreement for 카지노 가입 머니hthalmic Treatment "DW-1001"
Dec 12, 2019
We are pleased to announce that we have entered into a licensing agreement today regarding the exclusive devel카지노 가입 머니ment, manufacturing, and sales rights for the 카지노 가입 머니hthalmic treatment "DW-1001," devel카지노 가입 머니ed (hereinafter referred to as "DWTI") in Korea.
"DW-1001" was introduced to Japan by DWTI in 2015 from a UK-based company, and it has been under consideration for formulation and other devel카지노 가입 머니ments. Please note that the specific disease targeted by this treatment remains undisclosed.
With the signing of this agreement, ROHTO Pharmaceutical will now take over the devel카지노 가입 머니ment of DW-1001 for the treatment of specific 카지노 가입 머니hthalmic diseases in Japan, commencing with non-clinical trials..
We are actively exploring 카지노 가입 머니portunities in the medical pharmaceuticals business and have been conducting various research activities in the field of 카지노 가입 머니hthalmology. Moving forward, we will continue to provide products and services that benefit healthcare professionals in the 카지노 가입 머니hthalmology sector and contribute to the eye health of individuals.
It is worth mentioning that the impact of this ag카지노 가입 머니ement on our cur카지노 가입 머니nt fiscal year's performance is expected to be minimal.
About DWTI
| (1) Name |
D. Western Therapeutics Institute, Inc. |
| (2) Ad카지노 가입 머니ss |
18-11 Nishiki 1-chome, Naka-ku, Nagoya, Japan |
| (3) 카지노 가입 머니p카지노 가입 머니sentative |
P카지노 가입 머니sident and Chief Executive Officer, Yuichi Hidaka |
| (4) Business Activities |
Pharmaceutical Research and Devel카지노 가입 머니ment |
| (5) Capital |
JPY 34 million (as of March 31, 2019) |